-
公开(公告)号:US20180237542A1
公开(公告)日:2018-08-23
申请号:US15922778
申请日:2016-09-15
Applicant: AMGEN INC.
Inventor: Gunasekaran KANNAN , Michelle HORTTER , Edward J. BELOUSKI
CPC classification number: C07K16/468 , C07K16/00 , C07K16/241 , C07K16/2875 , C07K2317/14 , C07K2317/31 , C07K2317/35 , C07K2317/522 , C07K2317/56 , C07K2317/66 , C07K2317/90
Abstract: The present invention relates to tetravalent bispecific and tetraspecific antigen binding proteins that are capable of binding to multiple targets. Pharmaceutical compositions comprising the bispecific and tetraspecific antigen binding proteins as well as methods for producing them are also disclosed.
-
公开(公告)号:US20220213226A1
公开(公告)日:2022-07-07
申请号:US17379968
申请日:2021-07-19
Applicant: AMGEN INC.
Inventor: Hailing HSU , Gunasekaran KANNAN , Kenneth W. WALKER , Michelle HORTTER , Edward J. BELOUSKI
IPC: C07K16/46 , C07K16/24 , C07K16/28 , A61K39/395
Abstract: The present invention concerns antigen binding proteins that bind TL1A, including bispecific antigen binding proteins (e.g., antibodies) to TL1A and TNF-α. Such bispecific antibodies can be in a tetrameric immunoglobulin format, in which one heavy chain-light chain pair of the antibody is directed to TL1A and the other to TNF-α. The bispecific antigen binding proteins may also be comprised in an IgG-scFv fusion, in which a conventional tetrameric antibody directed to one antigen is fused to a pair of single chain Fv units directed to the other. The bispecific antigen binding protein may also be comprised in an IgG-Fab fusion, in which a Fab molecule that binds to one antigen is fused to each heavy chain of a conventional tetrameric antibody directed to the other antigen. The invention further relates to uses of the anti-TL1A binding proteins and anti-TL1A/anti-TNF-α antigen binding proteins, and pharmaceutical formulations thereof.
-
公开(公告)号:US20190119407A1
公开(公告)日:2019-04-25
申请号:US16062096
申请日:2016-12-14
Applicant: AMGEN INC.
Inventor: Hailing HSU , Gunasekaran KANNAN , Kenneth W. WALKER , Michelle HORTTER , Edward J. BELOUSKI
Abstract: The present invention concerns antigen binding proteins that bind TL1A, including bispecific antigen binding proteins (e.g., antibodies) to TL1A and TNF-α. Such bispecific antibodies can be in a tetrameric immunoglobulin format, in which one heavy chain-light chain pair of the antibody is directed to TL1A and the other to TNF-α. The bispecific antigen binding proteins may also be comprised in an IgG-scFv fusion, in which a conventional tetrameric antibody directed to one antigen is fused to a pair of single chain Fv units directed to the other. The bispecific antigen binding protein may also be comprised in an IgG-Fab fusion, in which a Fab molecule that binds to one antigen is fused to each heavy chain of a conventional tetrameric antibody directed to the other antigen. The invention further relates to uses of the anti-TL1A binding proteins and anti-TL1A/anti-TNF-α antigen binding proteins, and pharmaceutical formulations thereof.
-
4.
公开(公告)号:US20240010708A1
公开(公告)日:2024-01-11
申请号:US18238696
申请日:2023-08-28
Applicant: AMGEN INC.
Inventor: Jeonghoon SUN , Jason Charles O'NEILL , Randal R. KETCHEM , Randy Ira HECHT , Edward J. BELOUSKI , Mark Leo MICHAELS
IPC: C07K14/81
CPC classification number: C07K14/8146 , A61K38/00
Abstract: There are disclosed TIMP-3 muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them.
-
公开(公告)号:US20210047422A1
公开(公告)日:2021-02-18
申请号:US17005202
申请日:2020-08-27
Applicant: AMGEN INC.
Inventor: Gunasekaran KANNAN , Ling LIU , Edward J. BELOUSKI , Cen XU
Abstract: The present invention relates to bispecific antigen binding proteins that are capable of binding to both the human CGRP receptor and the human PAC1 receptor. Pharmaceutical compositions comprising the bispecific antigen binding proteins as well as methods for producing them are also disclosed. Methods of using the bispecific antigen binding proteins to ameliorate or treat conditions associated with the two receptors, such as chronic pain, migraine, and cluster headache, are also described.
-
6.
公开(公告)号:US20170306033A1
公开(公告)日:2017-10-26
申请号:US15511176
申请日:2015-09-15
Applicant: AMGEN INC.
Inventor: Gunasekaran KANNAN , Ling LIU , Edward J. BELOUSKI , Cen XU
IPC: C07K16/28
CPC classification number: C07K16/2869 , C07K16/18 , C07K16/28 , C07K2317/31 , C07K2317/35 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/70 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to bispecific antigen binding proteins that are capable of binding to both the human CGRP receptor and the human PAC1 receptor. Pharmaceutical compositions comprising the bispecific antigen binding proteins as well as methods for producing them are also disclosed. Methods of using the bispecific antigen binding proteins to ameliorate or treat conditions associated with the two receptors, such as chronic pain, migraine, and cluster headache, are also described.
-
-
-
-
-